FairJourney Biologics (FJB) and IONTAS, specialists in the discovery and optimisation of antibodies, have launched of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterisation data on antibody panels and leads.
As the market for antibody therapeutics continues to grow, there is, says FJB, an increased need for rapid purification and comprehensive antibody characterisation to support lead selection and enable a swift transition to manufacturing. FJB Group’s new division will focus on addressing the purification and characterisation needs for customers, from research institutions and start-ups to globally operating biotechnology and biopharmaceutical companies.
Flow Eighteen38 offers antibody production, from 96-well plates to deliver micrograms up to large scale, to deliver grams. The new services also comprise technologies for further functional and biophysical characterisation including mass spectrometry, SPR, DLS, SLS, cIEF, CE-SDS, and chromatography methods. The services include antigen production, for use as immunogens and to generate new antibodies and reagents for research.
Dr Antonio Parada, CEO at FJB, commented: “Flow Eighteen38 offers standalone, bespoke, antibody purification and characterization capabilities to our growing network. This is complementary to our mammalian display and phage display discovery platforms and will further reduce risk for our partners by selecting the right antibody lead for cell line development and manufacturing.”
Maria Pajuelo, CSO at FJB commented: “We see Flow Eighteen38 as a significant milestone in combining knowledge across our organisation into a new business unit. We look forward to expanding on our innovation in antibody discovery into the protein purification and characterisation space, to offer faster and quality solutions for our current and future partners.”
